Elutia signs agreement to sell SimpliDerm business for up to $11M, focuses on NXT-41x launch

ELUTIA INC.

Total consideration up to $11M: $8M cash at closing plus up to $3M in technology transfer and commercial milestone payments over 18 months.
Closing expected in H2 2026, subject to customary conditions; buyer is Cellution Biologics Inc.
Proceeds provide non-dilutive capital to advance NXT-41x toward clearance and commercial launch in 2027.
Divestiture sharpens Elutia's focus on the $1.5B plastic and reconstructive surgery market with NXT-41x.
SimpliDerm is a human acellular dermis product for breast reconstruction; sale completes strategic review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.